Prescription drug · NDA
Selzentry (maraviroc) NDC 50090-6238
Maraviroc 150 mg/1 · Tablet, Film coated · Oral · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-6238-0 | 50090623800 | 60 TABLET, FILM COATED in 1 BOTTLE (50090-6238-0)Marketed from Nov 29, 2022 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Selzentry
- Generic name (nonproprietary)
- maraviroc
- Active ingredients
- Maraviroc — 150 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- A-S Medication Solutions
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 022128
- Marketing start
- Listing expires
- Other FDA classes
- Chemokine Co-receptor 5 Antagonists (Mechanism)
- Identifiers
- Product ID 50090-6238_bb3c4af3-6c65-404e-821e-e9984e2b5878SPL ID bb3c4af3-6c65-404e-821e-e9984e2b5878SPL set ID 3c52dddd-0457-41cd-99e0-d30d4fd00ec5RxCUI 728223, 729201UNII MD6P741W8A
- Pharmacologic class
- CCR5 Co-receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450090623800followed by a unit qualifier and the quantityPackage 50090-6238-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
SELZENTRY is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients weighing at least 2 kg. Limitations of Use • SELZENTRY is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [see Microbiology ( 12.4 )]. SELZENTRY is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2 kg. ( 1 ) Limitations of Use: • Not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 022128
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.